Tearing Down The Goalposts (Part 2): Diabetes Debate Has Toned Down At US FDA

An October US FDA advisory committee meeting to discuss type 2 diabetes drug cardiovascular safety standards replayed a July 2008 meeting, but in a more harmonious key. That reflects the changing climate for FDA – but also a change in who was invited to participate.